|
KMID : 0387820010080010042
|
|
Clinical Pediatric Hematology-Oncology
2001 Volume.8 No. 1 p.42 ~ p.50
|
|
|
Detection of N-myc Amplification with Differential PCR in Neuroblastoma and It’s Clinical Significance
|
|
Kim Hwang-Min
Lee Chang-Hoon
Lee Chang-Hoon
Pakr Song-Hee
Kim Kil-Young
Kim Moon-Kyu
Cho Hyun-Sang
Lee Kwang-Chul
Lim Young-Tak
Park Seok-Won
Kim Heung-Sik
Kang Chin-Moo
Kang Im-Ju
Choi Seung-Hoon
Song Young-Tack
Yang Woo-Ick
|
|
|
Abstract
|
|
|
Purpose: The N-myc amplification is one of well known poor prognostic markers in neurblastoma. Because the traditional detection method, Southern blot, is expensive, labor-intensive and time-consuming, the detection of N-myc amplification is not
routinely performed in Korea. The purposes of this study are to develop polymerase chain reaction (PCR) for detecting N-myc amplification in neuroblastoma tumor tissue, and to elucidate the clinical significance of N-myc amplification. Methods:
The
clinical data and paraffin embedded tumor specimen of 54 neuroblastoma cases were collected from 10 medical
centers in Korea. We have developed semiquantitative method of estimating gene copy number that uses differential PCR. N-myc gene primers (RC N-myc, N-myc 7-1) are amplified together with primers from a single-copy internal control gene
(beta-globin).
After ethidium bromide-stained agarose gel electrophoresis, the ratio of the two PCR products, which stands for N-myc amplification, is determined. Kaplan-Meier survival analysis was performed to evaluate the prognostic significance of N-myc
amplification. Results: The differential PCR was very effective, less expensive, less labor-intensive, and simple detection method for N-myc amplification. The percentage of N-myc amplification was higher in the patients older than 1 year old
(34.1%:
14/41), when they were compared to the patients younger than 1 year old (16.7%: 2/12). The percentage of N-myc amplification was higher in the patients who have primary tumor at adrenal gland (40.9%: 9/22) than who have primary tumor at
retroperitoneum
(17.6%: 3/17) or at mediastinum (16.7%: 2/12). In Stage I, II, and III patients, the mean survival time of N-myc amplified group was 18 months and that of N-myc umamplified group was 64 months (Log Rank 4.35, P=0.037). Conclusion: The
differential
PCR
was very effective, less expensive, less labor-intensive, and simple detection method for N-myc amplification. The N-myc amplification is one of poor prognostic indicators in Neuroblastoma.
|
|
|
KEYWORD
|
|
|
Neuroblastoma, N-myc amplification, Prognosis, PCR,
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|
|